Cell Reports Physical Science,
Год журнала:
2023,
Номер
4(6), С. 101444 - 101444
Опубликована: Май 31, 2023
Endosomal
escape
remains
a
well-known
bottleneck
for
successful
small
interfering
RNA
(siRNA)
therapeutics.
Here,
chemical
electron
transfer
(CET)-based
self-activatable
lipopolyplex
is
explored
producing
singlet
oxygen
(1O2)
in
endosomes,
thereby
enhancing
siRNA
delivery.
The
simultaneously
encapsulates
bis(2,4,6-trichlorophenyl)
oxalate
(TCPO),
gold
nanoparticles
(GNs),
and
siRNA.
GNs
are
specifically
self-activated
by
the
transferred
energy
between
TCPO
hydrogen
peroxide,
which
enhanced
tumor
microenvironment.
Enhanced
endosomal
membrane
damage
verified
using
cytosolic
fluorescent
galectin-8
(Gal8)-mRuby
reporter;
oxidation
of
1O2
facilitates
rupture
endosomes
within
4
h,
improving
recruitment
Gal8
to
disrupted
up
∼50-fold.
This
research
demonstrates
that
CET
can
facilitate
nucleic
acids
from
cytosol
provides
starting
point
further
delivery
applications.
Skin
cancer
has
emerged
as
the
fifth
most
commonly
reported
in
world,
causing
a
burden
on
global
health
and
economy.
The
enormously
rising
environmental
changes,
industrialization,
genetic
modification
have
further
exacerbated
skin
statistics.
Current
treatment
modalities
such
surgery,
radiotherapy,
conventional
chemotherapy,
targeted
therapy,
immunotherapy
are
facing
several
issues
related
to
cost,
toxicity,
bioavailability
thereby
leading
declined
anti-skin
therapeutic
efficacy
poor
patient
compliance.
In
context
of
overcoming
this
limitation,
nanotechnological
advancements
been
witnessed
so
far.
Among
various
nanomaterials,
nanoparticles
endowed
exorbitant
advantages
by
acting
both
agents
drug
carriers
for
remarkable
cancer.
small
size
large
surface
area
volume
ratio
escalate
tumor
uptake
through
their
leaky
vasculature
resulting
enhanced
efficacy.
context,
present
review
provides
up
date
information
about
different
types
pathology
cancer,
followed
current
associated
drawbacks.
Furthermore,
it
meticulously
discusses
role
numerous
inorganic,
polymer,
lipid-based
therapy
with
subsequent
descriptions
patents
clinical
trials.
Journal of Hematology & Oncology,
Год журнала:
2024,
Номер
17(1)
Опубликована: Апрель 2, 2024
Abstract
Cancer
immunotherapy
and
vaccine
development
have
significantly
improved
the
fight
against
cancers.
Despite
these
advancements,
challenges
remain,
particularly
in
clinical
delivery
of
immunomodulatory
compounds.
The
tumor
microenvironment
(TME),
comprising
macrophages,
fibroblasts,
immune
cells,
plays
a
crucial
role
response
modulation.
Nanoparticles,
engineered
to
reshape
TME,
shown
promising
results
enhancing
by
facilitating
targeted
These
nanoparticles
can
suppress
fibroblast
activation,
promote
M1
macrophage
polarization,
aid
dendritic
cell
maturation,
encourage
T
infiltration.
Biomimetic
further
enhance
increasing
internalization
agents
cells
such
as
cells.
Moreover,
exosomes,
whether
naturally
secreted
body
or
bioengineered,
been
explored
regulate
TME
immune-related
affect
cancer
immunotherapy.
Stimuli-responsive
nanocarriers,
activated
pH,
redox,
light
conditions,
exhibit
potential
accelerate
co-application
with
checkpoint
inhibitors
is
an
emerging
strategy
boost
anti-tumor
immunity.
With
their
ability
induce
long-term
immunity,
nanoarchitectures
are
structures
development.
This
review
underscores
critical
overcoming
current
driving
advancement
modification.
Abstract
Rapid
growth
in
nanoparticles
(NPs)
as
delivery
systems
holds
vast
promise
to
promote
therapeutic
approaches
for
cancer
treatment.
Presently,
a
diverse
array
of
NPs
with
unique
properties
have
been
developed
overcome
different
challenges
and
achieve
sophisticated
routes
enhancement
series
therapies.
Inspiring
advances
achieved
the
field
therapy
using
NPs.
In
this
review,
we
aim
summarize
up‐to‐date
progression
addressing
various
challenges,
expect
elicit
novel
potential
opportunities
alternatively.
We
first
introduce
sorts
NP
technologies,
illustrate
their
mechanisms,
present
applications.
Then,
achievements
made
by
break
obstacles
delivering
cargoes
specific
sites
through
particular
are
highlighted,
including
long‐circulation,
tumor
targeting,
responsive
release,
subcellular
localization.
subsequently
retrospect
recent
research
treatments
from
single
therapy,
like
chemotherapy,
combination
chemoradiotherapy,
integrative
therapy.
Finally,
perspectives
impact
on
oncology
discussed.
believe
review
can
offer
deeper
understanding
Nature Communications,
Год журнала:
2023,
Номер
14(1)
Опубликована: Сен. 2, 2023
Abstract
Inhibition
of
glycolysis
in
immune
cells
and
cancer
diminishes
their
activity,
thus
combining
immunotherapies
with
glycolytic
inhibitors
is
challenging.
Herein,
a
strategy
presented
where
inhibited
using
PFK15
(inhibitor
PFKFB3,
rate-limiting
step
glycolysis),
while
simultaneously
function
rescued
DCs
by
delivery
fructose-1,6-biphosphate
(F16BP,
one-step
downstream
PFKFB3).
To
demonstrate
the
feasibility
this
strategy,
vaccine
formulations
are
generated
calcium-phosphate
chemistry,
that
incorporate
F16BP,
poly(IC)
as
adjuvant,
phosphorylated-TRP2
peptide
antigen
tested
challenging
established
YUMM1.1
tumours
immunocompetent
female
mice.
Furthermore,
to
test
versatility
adoptive
DC
therapy
developed
adjuvant
mRNA
derived
from
B16F10
antigens
F16BP
rescue
vitro
vivo,
significantly
improve
survival
mice,
generate
cytotoxic
T
cell
(Tc)
responses
elevating
Tc1
Tc17
within
tumour.
Overall,
these
results
rescuing
metabolite-based
can
be
utilized
immunotherapy
even
presence
inhibitor.
Nanoscale,
Год журнала:
2024,
Номер
16(27), С. 12820 - 12856
Опубликована: Янв. 1, 2024
This
review
extensively
explores
immunomodulatory
nanomedicines,
focusing
on
their
unique
properties
and
critical
design
strategies
for
interacting
with
immune
components
various
therapeutic
applications.
Combinations
of
chemotherapeutic
agents
comprise
a
clinically
feasible
approach
to
combat
cancers
that
possess
resistance
treatment.
Type
II
endometrial
cancer
is
typically
associated
with
poor
outcomes
and
the
emergence
chemoresistance.
To
overcome
this
challenge,
combination
therapy
developed
comprising
novel
ciprofloxacin
derivative-loaded
PEGylated
polymeric
nanoparticles
(CIP2b-NPs)
paclitaxel
(PTX)
against
human
type-II
(Hec50co
loss
function
p53).
Cytotoxicity
studies
reveal
strong
synergy
between
CIP2b
PTX
Hec50co,
significant
reduction
in
IC
